Sphingolipids are both structural and bioactive compounds. In particular, ceramide and sphingosine 1-phosphate regulate cell fate, inflammation and excitability. 1-α,25-dihydroxyvitamin D3 (1,25(OH)2D3) is known to play an important physiological role in growth and differentiation in a variety of cell types, including neural cells, through genomic actions mediated by its specific receptor, and non-genomic effects that result in the activation of specific signalling pathways. 1,25(OH)2D3 and sphingolipids, in particular sphingosine 1-phosphate, share many common effectors, including calcium regulation, growth factors and inflammatory cytokines, but it is still not known whether they can act synergistically. Alterations in the signalling and concentrations of sphingolipids and 1,25(OH)2D3 have been found in neurodegenerative diseases and fingolimod, a structural analogue of sphingosine, has been approved for the treatment of multiple sclerosis. This review, after a brief description of the role of sphingolipids and 1,25(OH)2D3, will focus on the potential crosstalk between sphingolipids and 1,25(OH)2D3 in neural cells
Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system
GARCIA GIL, MARIA de las MERCEDES;
2017-01-01
Abstract
Sphingolipids are both structural and bioactive compounds. In particular, ceramide and sphingosine 1-phosphate regulate cell fate, inflammation and excitability. 1-α,25-dihydroxyvitamin D3 (1,25(OH)2D3) is known to play an important physiological role in growth and differentiation in a variety of cell types, including neural cells, through genomic actions mediated by its specific receptor, and non-genomic effects that result in the activation of specific signalling pathways. 1,25(OH)2D3 and sphingolipids, in particular sphingosine 1-phosphate, share many common effectors, including calcium regulation, growth factors and inflammatory cytokines, but it is still not known whether they can act synergistically. Alterations in the signalling and concentrations of sphingolipids and 1,25(OH)2D3 have been found in neurodegenerative diseases and fingolimod, a structural analogue of sphingosine, has been approved for the treatment of multiple sclerosis. This review, after a brief description of the role of sphingolipids and 1,25(OH)2D3, will focus on the potential crosstalk between sphingolipids and 1,25(OH)2D3 in neural cellsFile | Dimensione | Formato | |
---|---|---|---|
Garcia-Gil_et_al-2017-British_Journal_of_Pharmacology.pdf
solo utenti autorizzati
Tipologia:
Versione finale editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.56 MB
Formato
Adobe PDF
|
1.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Fig 4 finali review BJP 12 dic.pdf
accesso aperto
Descrizione: figura 4
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
24.47 kB
Formato
Adobe PDF
|
24.47 kB | Adobe PDF | Visualizza/Apri |
Fig 3 new.pdf
accesso aperto
Descrizione: figura 3
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
513.1 kB
Formato
Adobe PDF
|
513.1 kB | Adobe PDF | Visualizza/Apri |
Fig 2.pdf
accesso aperto
Descrizione: figura 2
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
429.91 kB
Formato
Adobe PDF
|
429.91 kB | Adobe PDF | Visualizza/Apri |
Fig 1B.pdf
accesso aperto
Descrizione: figura 1B
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
430.41 kB
Formato
Adobe PDF
|
430.41 kB | Adobe PDF | Visualizza/Apri |
figure 1A SL metabolism.pdf
accesso aperto
Descrizione: figura 1A
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
161.71 kB
Formato
Adobe PDF
|
161.71 kB | Adobe PDF | Visualizza/Apri |
Garcia-Gil et al. BJP 190117 +tables.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
473.97 kB
Formato
Adobe PDF
|
473.97 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.